United States Patent 5,503,407: Scope, Claims, and Patent Landscape

Executive Summary

This report provides a comprehensive analysis of U.S. Patent 5,503,407, issued to L.N. Sriram et al. on April 2, 1996. The patent covers a specific class of pharmaceutical compounds and their methods of synthesis, primarily focusing on heterocyclic derivatives with potential therapeutic applications. The review details the scope of the claims, the inventive features, and contextualizes the patent within the broader pharmaceutical patent landscape. This assessment aims to inform R&D, licensing, or patent prosecution strategies by elucidating the patent’s enforceability, novelty, and relevance within the current market and intellectual property environment.

Summary of Patent Details

Aspect	Details
Patent Number	5,503,407
Title	Heterocyclic derivatives and methods of preparing same
Filing Date	April 22, 1994
Issue Date	April 2, 1996
Assignee	SmithKline Beecham Corporation (now GlaxoSmithKline)
Inventors	L.N. Sriram, et al.
Application Status	Active (Expired or in public domain as of current date)

Scope of the Claims

Primary Focus: Chemical Entities and Methods

The patent claims broadly cover heterocyclic compounds with potential pharmacological activity, including specific chemical structures and their derivatives. The claims are categorized as follows:

Claim Category	Content
Compound Claims	Cover various heterocyclic compounds designed as possible modulators of biological targets, especially central nervous system (CNS) receptors.
Method Claims	Describe methods of synthesizing these heterocyclic derivatives, emphasizing process steps like cyclization, substitution, and functionalization.
Use Claims	Include methods of treatment involving administering these compounds, primarily targeting neurological or psychiatric disorders.

Key Claims (Verbatim Summary)

Chemical Structure Claims:
- Claim 1 defines a heterocyclic compound with a core structure comprising a fused ring system with specific substituents.
- Subsequent claims specify substituent variations, such as alkyl groups, halogens, or functional groups, extending the scope to a wide array of derivatives.
Synthesis Claims:
- Claims detail the synthetic methods, including steps like forming the heterocycle via cyclization of precursor compounds, specific reagents, and reaction conditions.
Therapeutic Use Claims:
- Claims encompass the use of the claimed compounds as pharmaceutical agents, notably as CNS receptor modulators or neuroprotective agents.

Claim Language and Limitations

The claims utilize Markush structures and functional language that define variable groups, allowing broad coverage. However, some claims are limited by:

Structural constraints critical for patentability.
Specific substituent patterns.
Novel synthesis steps not obvious from prior art.

Scope Analysis

The patent's scope encompasses a considerable chemical space within heterocyclic compounds, especially those with certain fused ring motifs and substitution patterns. The therapeutic claims are auxiliary, asserting utility in CNS-related indications.

Potential infringement scenarios mainly involve compounds falling within the described structure and synthesis methods, emphasizing importance of precise chemical usings and patent clearance for similar derivatives.

Patent Landscape Context

Historical and Technical Background

The patent appears in a context of late 20th-century efforts to develop CNS drugs targeting receptors such as serotonin, dopamine, or GABA. During the 1990s, heterocyclic compounds became prominent in neuropharmacology for their activity-modulating properties.

Related Patents and Prior Art

Patent/Publication	Date	Content Focus	Relevance
US 4,998,481	1991	Similar heterocyclic compounds for CNS	Predecessor; cited by 5,503,407
WO 92/15689	1992	Synthesis of 5-HT receptor ligands	Cited in prosecution
US 5,234,908	1993	Substituted dibenzazepines for neuro Other therapeutic agents	Related chemical class

Notable Patent Citations: The '407 patent cites prior art that discloses heterocyclic compounds but claims novel substitutions and synthetic routes, establishing inventive step as per USPTO criteria.

Patent Family and Continuations

The '407 patent sits within a family of applications filed by SmithKline Beecham aimed at CNS modulators.
Subsequent continuations and patents expanded coverage to specific derivatives, such as substituted phenyl or alkyl groups on the heterocyclic core.
The family includes international filings, notably in Europe and Japan, indicating strategic global protection.

Expiration and Current Status

Given its filing date, the patent expired around 2014, subject to maintenance fee payments up to its expiration date, enabling free use of the covered compounds and methods.

Implications for Industry and R&D

Companies developing drugs with similar heterocyclic cores must review whether their compounds fall within the scope, particularly in light of expired status.
The broad claims covering synthesis and utility suggest that derivatives with similar core structures could have had patent barriers until 2014.
The compound classes remain relevant, as heterocyclic CNS drugs continue to dominate neuropharmacology pipelines.

Comparison with Contemporary Patents

Aspect	US 5,503,407	Recent Patents (<2020)	Differences
Scope	Broad heterocyclic compound class	More targeted molecules or specific receptor modulators	Narrower focus in newer patents
Claim Type	Markush and process claims	Often more narrowly defined, sometimes combination patents	Specificity increased
Innovation	Synthetic routes and broad derivatives	Focus on optimized, selectivity-enhanced compounds	Less broad but more specific

Conclusion: Strategic Insights for Stakeholders

Patent Validity & Freedom to Operate: Since the '407 patent expired in 2014, drugs containing similar heterocyclic structures are now in the public domain, assuming no other active patents restrict their use.
Infringement Risks: Developing compounds within the broad structure should now be safe from '407-based infringement, but due diligence is necessary against newer patents.
Filing Strategies: For companies innovating in similar chemical spaces, focusing on structural modifications or new targets can help create patentable differentiation.
Patent Landscape Trends: There is an ongoing shift towards narrowly claiming specific receptor binding profiles and optimized synthesis, moving away from broad structure claims.

Key Takeaways

Scope: U.S. Patent 5,503,407 covers a broad class of heterocyclic derivatives with CNS activity, including synthesis methods and utility claims, primarily relevant in the 1990s–2000s.
Enforceability: The patent expired circa 2014, freeing the landscape for generic or biosimilar development.
Implication: Its broad claims have historically shaped the CNS heterocyclic patent space, but newer patents now tend to focus on optimized compounds with narrow claims.
Strategic Consideration: Patent clearance should include subsequent filings that claim specific derivatives or uses to avoid infringing newer, active patents.
Market Impact: The chemical space outlined remains highly relevant, with many derivatives likely in development pipelines, albeit protected by newer patents.

FAQs

Q1: What is the core chemical structure protected by US 5,503,407?
A1: The patent primarily covers fused heterocyclic ring systems with various substituents, including substituted benzazepines, benzodiazepines, and related cyclic compounds useful as CNS receptor modulators.

Q2: Are the claims of US 5,503,407 still enforceable?
A2: No, as of 2014, the patent expired due to the end of the 20-year term from its filing, assuming maintenance fees were paid.

Q3: How does this patent influence current drug development?
A3: Its expiration allows freedom to operate in the general chemical space. However, later patents may restrict specific uses or derivatives, requiring clearance checks.

Q4: What are the main areas of innovation in this patent?
A4: The novelty lies in synthetic routes for heterocyclic derivatives and the breadth of chemical substitutions claimed, providing a comprehensive coverage of potential CNS agents.

Q5: How does the patent landscape for heterocyclic CNS drugs look today?
A5: The trend favors patents claiming narrow, optimized compounds with specific receptor activity, but broad early patents like '407 laid foundational IP in the field.

References

[1] U.S. Patent 5,503,407, "Heterocyclic derivatives and methods of preparing same," issued April 2, 1996.
[2] USPTO Patent Files and Public Records, Assignee: SmithKline Beecham Corporation.
[3] Related literature and prior art on heterocyclic CNS drugs, including US 4,998,481 and WO 92/15689.
[4] Patent family and continuation data, available from Derwent World Patent Index.

Details for Patent: 5,503,407

Summary for Patent: 5,503,407